Significant Improvement In Progression-Free Survival For Triple Negative Metastatic B
 

Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA? (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer.

More...